FDA
-
-
-
-
-
-
-
Nkarta Inc. (NKTX) PT Lowered to $11 at Stifel
-
-
-
-
-
-
-
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
-
-
-
-
-
-
-
Pre-Open Stock Movers 04/26: MagnaChip Gains on Deal Talk; Universal Health, GE Dip on Earnings (more...)
-
-
-
-
-
-
-
Nkarta Announces Updates to NKX019 and NKX101 Clinical Development Programs
-
-
-
-
-
-
-
Nkarta (NKTX) Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
-
-
328,140 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

